Posted by Michael Wonder on 01 Mar 2022
EMA accepts marketing authorisation application for daprodustat
1 March 2022 - Submission for the treatment of anaemia of chronic kidney disease based on the ASCEND Phase III clinical trial programme, consisting of five trials that all met their co-primary efficacy and safety endpoints.
GlaxoSmithKline today announced that the EMA validated the marketing authorisation application for daprodustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for the treatment of patients with anaemia of chronic kidney disease.
